.Pharmacolibrary.Drugs.ATC.J.J01MA24 .Pharmacolibrary.Drugs.ATC.J.J01MA24| name: | Levonadifloxacin | |
| ATC code: | J01MA24 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 800 | mg |
| volume of distribution: | 14.8 | L |
| clearance: | 7.0 | L/h |
| other parameters in model implementation | ||
Levonadifloxacin is a broad-spectrum, novel benzoquinolizine fluoroquinolone antibiotic used primarily for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital-acquired pneumonia. It is effective against Gram-positive pathogens including methicillin-resistant Staphylococcus aureus (MRSA). Levonadifloxacin has been approved for clinical use in India.
Pharmacokinetic parameters for healthy adult subjects following intravenous administration.
Bhatia, A, et al., & Friedland, HD (2020). Efficacy and Safety of a Novel Broad-Spectrum Anti-MRSA Agent Levonadifloxacin Compared with Linezolid for Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Openlabel, Randomized Study. The Journal of the Association of Physicians of India 68(8) 30–36. PUBMED:https://pubmed.ncbi.nlm.nih.gov/32738837